Pfizer Abandons Weight Loss Drug, Stock Drops.
Pfizer has discontinued the development of its once-a-day experimental obesity pill, lotiglipron, due to concerns about liver safety. However, the company will continue developing its twice-daily treatment, danuglipron, as it competes with other weight loss treatments. Pfizer CEO Albert Bourla has said that an obesity pill could eventually be a $10-billion-a-year product for Pfizer. The news comes after competitor Eli Lilly released promising data for its own once-daily experimental pill, orforglipron.